UNSPSC 51372102: 3-methylmorphine or codeine

This classification denotes an opiate with the molecular formula C18H21NO3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q830PW7520, chemically known as codeine, sulfate but generally known as codeine, which bears US NIH Compound Identifier 223652. European Medicines Agency schedules Codeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13424MIG. World Health Organization schedules codeine in its Anatomical Therapeutic Chemical (ATC) Classification.

3-methylmorphine or codeine bears US NLM identifiers UMLS ID C0009214 and NCI Concept Code C383. SMILES: S(=O)(=O)(O)O.O1C2C34C(C(N(CC3)C)CC3C4C1C(OC)CC3)C=CC2O.

UNSPSC 51372102 3-methylmorphine or codeine is a Commodity code that covers pharmaceutical products procured by state and local health agencies, primarily in the context of public health initiatives, pharmacy benefit programs, and emergency response systems. Recent state and local solicitations under this code reflect demand for controlled pharmaceuticals and related health-system products distributed through established supply channels, though the actual opportunities posted show significant variation from the code's nominal scope — ranging from opioid-antagonist procurement (naloxone) to generic pharmaceutical supply agreements to direct-to-manufacturer prescription models. Issuing bodies include state health and human services departments, county public health offices, and cooperative purchasing alliances spanning multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission represent active state-level buyers; Seminole County, Florida signals county-level procurement activity in the space.

Geographic activity centers on the Upper Midwest and South. Minnesota's MMCAP cooperative, which serves multiple state and local participants across regions including Oregon, posted a generic multi-source pharmaceuticals RFP on January 20, 2026, with a response deadline of March 26, 2026, requiring vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) with pricing submissions weighted 75 percent on competitiveness and 25 percent on administrative and operational compliance. Texas HHS issued a Request for Information on April 3, 2026, to explore direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager arrangements. Seminole County, Florida released an IFB on June 30, 2026 (due July 26, 2023 per the source date) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Vendors across these solicitations must meet DEA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and insurance requirements including commercial general liability coverage up to $5 million.